🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

BRIEF-Bard1 Life Sciences updates on status of lung cancer diagnostics program

Published 18/04/2017, 04:22 pm
© Reuters.  BRIEF-Bard1 Life Sciences updates on status of lung cancer diagnostics program
IIQ
-

April 18 (Reuters) - Bard1 Life Sciences Ltd BD1.AX :

* Says gives update on status of its lung cancer diagnostics program

* Says it had expected to announce results of its lung cancer by end of March 2017

* Bard1 Life Sciences says data is still undergoing analysis and determine performance of Bard1 test for early detection of lung cancer

* Bard1 life sciences says to report results of study after completion of analysis; process expected to take up to 8 weeks Source text for Eikon: Further company coverage: BD1.AX

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.